|
Telmisartan in daily clinical practice: Factors affecting efficacy in treatment of primary arterial hypertension
M Bergovac1, A Knezevic2, D Plavec3, V Trkulja4
1 Department of Cardiology, University Hospital Dubrava, Zagreb University School of Medicine, Zagreb, Croatia
2 Cardiology Unit, Zadar County Hospital, Zadar, Croatia
3 Institute for Medical Research and Occupational Health, Zagreb, Croatia
4 Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia
Correspondence Address:
V Trkulja
Department of Pharmacology, Zagreb University School of Medicine, Zagreb
Croatia
Background: Telmisartan provides effective treatment of hypertension in a broad spectrum of patients. Aims: To evaluate factors affecting the efficacy of telmisartan in daily clinical practice. Setting and Design: Prospective practice-based 12-week uncontrolled cohort study. Materials and Methods: Consecutive incident/prevalent outpatients with mild to moderate essential hypertension were started on telmisartan 40 mg/day with optional up-titration to 80 mg/day in order to achieve seated systolic (SSBP) and diastolic (SDBP) blood pressure <140/90 mm Hg. Intent-to-treat (ITT, N=282) and per protocol (PP, N=275) efficacy assessment was based on SSBP/SDBP reduction and delivered doses. Results: SSBP/SDBP decreased (165.2±13.1 / 98.3±6.7 mm Hg to 137.9±13.2 / 82.6±7.3 mm Hg), whilst telmisartan was up-titrated in 40.5% of patients during the study. Multivariate (practically identical ITT and PP) analysis indicated poorer response in obese vs. non-obese patients: lesser SDBP reduction (by around 2.2-2.3 mm Hg, P <0.05) with higher odds of dose up-titration (odds ratio, OR around 1.90, P <0.05); and better response in: a) patients started on telmisartan monotherapy than when added to a preexisting treatment: greater SSBP/SDBP reduction (by around 4.0 and 3.0 mm Hg, respectively, P <0.05) with comparable odds of up-titration; b) diabetics vs. non-diabetics: greater SDBP reduction (by around 3.6-3.7 mm Hg, P <0.05) with comparable odds of up-titration; c) men vs. women: slightly greater SDBP reduction (by around 1.2 mm Hg, 0.05< P <0.1) with lower odds of up-titration (OR around 0.51, P <0.05). Conclusion: Previous unsuccessful treatment, obesity, diabetes and gender should be considered in order to optimize the use of telmisartan for mild to moderate essential hypertension in daily clinical practice.
How to cite this article:
Bergovac M, Knezevic A, Plavec D, Trkulja V. Telmisartan in daily clinical practice: Factors affecting efficacy in treatment of primary arterial hypertension.J Postgrad Med 2009;55:27-32
|
How to cite this URL:
Bergovac M, Knezevic A, Plavec D, Trkulja V. Telmisartan in daily clinical practice: Factors affecting efficacy in treatment of primary arterial hypertension. J Postgrad Med [serial online] 2009 [cited 2023 Mar 31 ];55:27-32
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2009;volume=55;issue=1;spage=27;epage=32;aulast=Bergovac;type=0 |
|
